NovaBay Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$5.25 | -$5.25 | -$5.25 |
| Q2 2024 | 1 | -$1.23 | -$1.23 | -$1.23 |
| Q3 2024 | 1 | -$0.31 | -$0.31 | -$0.31 |
| Q4 2024 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q1 2025 | 1 | -$0.32 | -$0.32 | -$0.32 |
| Q2 2025 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q3 2025 | 1 | -$0.26 | -$0.26 | -$0.26 |
| Q4 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
| Q1 2026 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q2 2026 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q3 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q4 2026 | 1 | $0.03 | $0.03 | $0.03 |
NovaBay Pharmaceuticals, Inc. Earnings Date And Information
NovaBay Pharmaceuticals, Inc. last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-1.37 earnings per share for the quarter, missing analysts' consensus estimates of $-1.22 by $0.15. The company had revenue of 2.40 M for the quarter and had revenue of 14.73 M for the year. NovaBay Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-2.29 diluted earnings per share) and currently has a price-to-earnings ratio of -0.08. NovaBay Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
NovaBay Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2024 | Q2 2024 | -$1.22 | -$1.37 | -0.15 | $2.40 M | $2.40 M |
| 05/09/2024 | Q1 2024 | -$1.22 | -$0.13 | 1.09 | $2.63 M | |
| 03/29/2024 | Q4 2023 | -$0.37 | $3.73 M | |||
| 11/09/2023 | Q3 2023 | -$0.40 | -$0.37 | 0.03 | $3.55 M | $3.26 M |
| 08/10/2023 | Q2 2023 | -$0.56 | -$1.27 | -0.71 | $3.70 M | $4.61 M |
| 05/11/2023 | Q1 2023 | -$0.91 | -$0.85 | 0.06 | $3.12 M | |
| 04/28/2023 | Q4 2022 | -$4.33 | $3.64 M | |||
| 11/14/2022 | Q3 2022 | -$1.23 | -$3.61 | -2.38 | $3.75 M | $3.83 M |
| 08/11/2022 | Q2 2022 | -$1.40 | -$1.43 | -0.03 | $3.50 M | $3.05 M |
| 05/12/2022 | Q1 2022 | -$1.05 | -$0.08 | 0.97 | $2.63 M | |
| 03/29/2022 | Q4 2021 | -$1.75 | -$0.69 | 1.06 | $2.64 M | |
| 11/12/2021 | Q3 2021 | -$1.78 | $2.45 M | $1.84 M | ||
| 08/12/2021 | Q2 2021 | -$1.40 | -$1.53 | -0.13 | $2.00 M | $2.13 M |
| 05/06/2021 | Q1 2021 | -$1.40 | -$1.27 | 0.13 | $1.81 M | |
| 03/25/2021 | Q4 2020 | -$1.47 | $1.89 M | |||
| 11/12/2020 | Q3 2020 | -$1.40 | -$2.82 | -1.42 | $2.53 M | $2.17 M |
| 08/06/2020 | Q2 2020 | -$1.75 | -$5.16 | -3.41 | $3.00 M | $3.98 M |
| 05/07/2020 | Q1 2020 | -$2.45 | -$1.98 | 0.47 | $1.89 M | |
| 03/26/2020 | Q4 2019 | -$2.45 | -$4.42 | -1.97 | $1.70 M | |
| 11/07/2019 | Q3 2019 | -$2.80 | -$0.54 | 2.26 | $2.05 M | $1.62 M |
NovaBay Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is NovaBay Pharmaceuticals, Inc.'s earnings date?
NovaBay Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
How can I listen to NovaBay Pharmaceuticals, Inc.'s earnings conference call?
The conference call for NovaBay Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read NovaBay Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for NovaBay Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does NovaBay Pharmaceuticals, Inc. generate each year?
NovaBay Pharmaceuticals, Inc. (:NBY) has a recorded annual revenue of $14.73 M.
-
How much profit does NovaBay Pharmaceuticals, Inc. generate each year?
NovaBay Pharmaceuticals, Inc. (:NBY) has a recorded net income of $14.73 M. NovaBay Pharmaceuticals, Inc. has generated $-2.29 earnings per share over the last four quarters.
-
What is NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio?
NovaBay Pharmaceuticals, Inc. (:NBY) has a price-to-earnings ratio of -0.08 and price/earnings-to-growth ratio is 0.02.
